Hashimoto H et al., 2009-12: Early in vitro paper reporting that ivermectin inhibits PAK1 and suppresses PAK1-dependent growth of human ovarian cancer and NF2-deficient schwannoma cell lines at IC50 5-20 micromolar, and reviewing prior mouse xenograft reports of 3-5 mg/kg dosing.
Here we demonstrate for the first time that Ivermectin blocks the oncogenic kinase PAK1 in human ovarian cancer and NF2-deficient Schwannoma cell lines to suppress their PAK1-dependent growth in cell culture, with the IC50 between 5-20 μM depending on cell lines.
n/a (PubMed abstract)
Hashimoto H et al., 2009-12: Early in vitro paper reporting that ivermectin inhibits PAK1 and suppresses PAK1-dependent growth of human ovarian cancer and NF2-deficient schwannoma cell lines at IC50 5-20 micromolar, and reviewing prior mouse xenograft reports of 3-5 mg/kg dosing. Study type: cell lines only. N: n/a. Country: Japan/Australia (NF Cure, Japan; Melbourne). Dose: in vitro IC50 5-20 uM. Funder/COI: not stated in the record. Comparator: untreated/PAK1-deficient controls. CORRECTION TO LEAD: the prompt attributes the ovarian PAK1 work to 'Wang K et al.'; the ovarian/NF2 PAK1 paper is Hashimoto et al. 2009, while Wang K et al. 2016 (IVC-18) is the breast cancer autophagy paper. The abstract also relays, without independent verification, an earlier Russian group's report of 3-5 mg/kg xenograft activity. Study type: lab.
